As longevity research increases, the focus is shifting from bold claims to the evidence needed to support meaningful clinical progress.
In this episode of the Olink Proteomics in Proximity podcast, the hosts discuss insights from leaders across the FDA, ARPA-H, XPRIZE, academia, and industry, exploring how regulatory frameworks, large-scale proteomics studies, and biomarker-driven research are helping shape the future of healthy aging.
For research use only. Not for use in diagnostic procedures.
About Olink®- Part of Thermo Fisher Scientific
Olink’s mission is to accelerate proteomics together with the scientific community, to understand real-time biology and gain actionable insights into human health and disease. Our innovative solutions deliver highly sensitive and accurate protein quantification, giving scientists the power to investigate complex biological processes with precision.
One platform. Endless possibilities.
Explore up to 5,400 proteins with high specificity, transparent data, and the flexibility to answer any research question. Meet the next-generation proteomics platform trusted by the scientific community, from small academic research teams through to leading pharma companies.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.